Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries M Brisson, JJ Kim, K Canfell, M Drolet, G Gingras, EA Burger, D Martin, ... The Lancet 395 (10224), 575-590, 2020 | 639 | 2020 |
Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries K Canfell, JJ Kim, M Brisson, A Keane, KT Simms, M Caruana, EA Burger, ... The Lancet 395 (10224), 591-603, 2020 | 460 | 2020 |
Potential cost‐effectiveness of the nonavalent human papillomavirus (HPV) vaccine M Drolet, JF Laprise, MC Boily, EL Franco, M Brisson International Journal of Cancer 134 (9), 2264-2268, 2014 | 196* | 2014 |
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model–based analysis N Van de Velde, MC Boily, M Drolet, EL Franco, MH Mayrand, EV Kliewer, ... Journal of the National Cancer Institute 104 (22), 1712-1723, 2012 | 172 | 2012 |
Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States M Brisson, JF Laprise, HW Chesson, M Drolet, T Malagón, MC Boily, ... Journal of the National Cancer Institute 108 (1), djv282, 2016 | 103 | 2016 |
The estimated direct lifetime medical costs of sexually transmitted infections acquired in the United States in 2018 HW Chesson, IH Spicknall, A Bingham, M Brisson, ST Eppink, ... Sexually Transmitted Diseases 48 (4), 215-221, 2021 | 102 | 2021 |
Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model M Jit, M Brisson, JF Laprise, YH Choi Bmj 350, 2015 | 91 | 2015 |
Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States JF Laprise, HW Chesson, LE Markowitz, M Drolet, D Martin, É Bénard, ... Annals of internal medicine 172 (1), 22-29, 2020 | 89 | 2020 |
Comparing the cost-effectiveness of two-and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study JF Laprise, M Drolet, MC Boily, M Jit, C Sauvageau, EL Franco, ... Vaccine 32 (44), 5845-5853, 2014 | 85 | 2014 |
Estimated prevalence and incidence of disease-associated human papillomavirus types among 15-to 59-year-olds in the United States RM Lewis, JF Laprise, JW Gargano, ER Unger, TD Querec, HW Chesson, ... Sexually transmitted diseases 48 (4), 273-277, 2021 | 75 | 2021 |
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study M Brisson, JF Laprise, M Drolet, N Van de Velde, EL Franco, EV Kliewer, ... Vaccine 31 (37), 3863-3871, 2013 | 75 | 2013 |
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical … M Drolet, JF Laprise, D Martin, M Jit, É Bénard, G Gingras, MC Boily, ... The Lancet Infectious Diseases 21 (11), 1598-1610, 2021 | 60 | 2021 |
Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination M Drolet, MC Boily, C Greenaway, SL Deeks, C Blanchette, JF Laprise, ... Cancer epidemiology, biomarkers & prevention 22 (4), 641-652, 2013 | 58 | 2013 |
Ultrafast laser-induced melting of glass V Koubassov, JF Laprise, F Théberge, E Förster, R Sauerbrey, B Müller, ... Applied Physics A 79, 499-505, 2004 | 55 | 2004 |
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling … KT Simms, JF Laprise, MA Smith, JB Lew, M Caruana, M Brisson, ... The Lancet Public Health 1 (2), e66-e75, 2016 | 52 | 2016 |
Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis JF Laprise, LE Markowitz, HW Chesson, M Drolet, M Brisson The Journal of infectious diseases 214 (5), 685-688, 2016 | 50 | 2016 |
Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine HW Chesson, JF Laprise, M Brisson, LE Markowitz The Journal of infectious diseases 213 (11), 1694-1700, 2016 | 38 | 2016 |
The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation M Drolet, JF Laprise, JML Brotherton, B Donovan, CK Fairley, H Ali, ... The Journal of Infectious Diseases 216 (10), 1205-1209, 2017 | 37 | 2017 |
Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review G Gingras, MH Guertin, JF Laprise, M Drolet, M Brisson PloS one 11 (9), e0163880, 2016 | 37 | 2016 |
Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? M Jit, YH Choi, JF Laprise, MC Boily, M Drolet, M Brisson Vaccine 32 (26), 3237-3242, 2014 | 37 | 2014 |